Coherus BioSciences (CHRS) 2025 Conference June 04, 2025 05:30 PM ET Speaker0 Good afternoon. Welcome to the Jefferies Global Healthcare Conference. My name is Ryan Delaney with the Jefferies Investment Banking team. It's my pleasure to introduce Denny Lanphier, CEO of Coherus Biosciences. Speaker1 Thank you. Thank you, Ryan, and thank you to the bank for your kind invitation to this year's conference. I also wanna thank the bank for your kind assistance with respect to closing out of our $230,000,000 conve ...

REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a significant play ...

纪要涉及的公司 Coherus BioSciences (CHRS) 纪要提到的核心观点和论据 1. **公司转型**：过去一年公司剥离了价值8亿美元的生物仿制药业务，包括Lucentis、Yosemir和UDENYCA生物仿制药，还清了4.8亿美元长期债务，交易完成时资产负债表增加约2.5亿美元，成功转型为创新肿瘤公司[3]。 2. **Loktorzi（Torapalumab）** - **市场表现**：鼻咽癌适应症首年增长良好，Q4表现佳，但Q1因UDENYCA供应中断、销售团队精力分散和库存积压等因素增长平缓，Q2恢复良好增长[10][11][12]。 - **市场策略**：聚焦扩大处方医生数量和医疗机构范围（广度）、提高市场渗透率（深度）、确保患者持续用药并获得最大收益（持续时间），同时推动医生遵循NCCN指南使用Loktorzi联合化疗[12][13]。 - **合作拓展**：与Storm Therapeutics的STC 15开展联合临床研究，用于头颈部癌、非小细胞肺癌、黑色素瘤和子宫内膜癌等，首名患者已给药并正在积极招募，后续还会有其他合作和肿瘤类型的公告[16][17][18]。 - **目标**：以Torapalumab为基础推动潜在的标签扩展，积累西方人群数据，支持公司试验[20]。 3. **CHS 114** - **作用机制**：CCR8靶向抗体，选择性抑制CCR8，优先靶向肿瘤驻留Treg细胞，避免广泛耗竭Treg细胞导致自身免疫[24]。 - **临床数据**：一期临床研究显示耐受性良好的安全概况、剂量成比例的药代动力学，在药理学活性剂量下实现肿瘤内Treg细胞52 - 97%的耗竭和CD8 T细胞的高浸润，将冷肿瘤转变为热肿瘤；与Toripalumab联合治疗晚期头颈部癌患者，一名四线患者有显著部分缓解[25][26][27]。 - **研究进展**：正在积极招募二线头颈部癌患者与Torapalumab联合治疗，以克服PD - 1耐药；开展胃癌研究，内部也在寻找其他肿瘤类型加入研究方案[28][29]。 - **竞争优势**：是唯一对CCR8有独家结合的分子，无脱靶毒性，而三个竞争对手项目均有脱靶结合[32]。 4. **casdozoketug** - **作用机制**：抗IL - 27细胞因子的抗体，抑制该细胞因子可重新平衡免疫系统，在肿瘤学中首次证明具有良好安全性，适合联合治疗[40]。 - **临床数据**：单药治疗在肺癌和肝癌中有反应，与atezo和bev联合治疗30名患者的二期研究中，总体缓解率38%、无进展生存期8.1个月，完全缓解率17%，高于一线肝细胞癌（HCC）三期研究报告[41][42]。 - **研究进展**：HCC随机研究正在招募患者，预计明年出数据；肺癌研究与合作组在规划中，正式宣布研究启动和进展是下一个里程碑[44]。 其他重要但是可能被忽略的内容 公司在开发、监管事务和商业方面有良好记录，尤其在商业方面表现出色，未来将聚焦执行，Theresa团队在制定和推进开发项目方面表现优秀[48][49]。

– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small ...

Coherus BioSciences (CHRS) FY 2025 Conference May 20, 2025 12:00 PM ET Speaker0 Represented by the company's CEO, Danny Lanfear, and the chief scientific officer Speaker1 Scientific and development Speaker0 officer. Scientific and development officer to Theresa Lavelle. So, Denny, I don't know if you know this, but I think we're now have known each other for a decade, which makes me feel kind of old. But the company certainly evolved and changed dramatically from when we first got to know each other as a as ...

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.90%. A quarter ago, it was expected that this drug developer would post a loss of $0.23 per share when it actually produced a loss of $0.28, delivering a surprise of -21.74%.Over the last four quarters, the company ...

Coherus BioSciences (CHRS) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Company Participants Jodi Sievers - Vice President of Investor Relations & Corporate CommunicationsDennis Lanfear - Chairman, President & CEOTheresa Lavallee - Chief Scientific & Development OfficerRosh Dias - Chief Medical OfficerSameer Goregaoker - EVP - CommercialBryan McMichael - CFOKripa Devarakonda - Vice President - Biotechnology Equity ResearchMichael Nedelcovych - Director - Equity Research Conference Call Participants Brian ...

Coherus BioSciences (CHRS) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Coherus Biosciences First Quarter twenty twenty five Earnings Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jody Sievers, Head of Investor R ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inco ...

Exhibit 99.1 Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1 ...